A prospective study assessing the real world effectiveness of casirivimab plus indevimab in a dedicated ambulatory unit created for patients with early COVID-19 during a massive delta variant wave
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Casirivimab/imdevimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 05 Aug 2022 New trial record
- 27 Jul 2022 Results published in the European Journal of Clinical Microbiology and Infectious Diseases